Back to Sectors

BTAI

BioXcel Therapeutics, Inc.
3 filings tracked
healthcarebiotechnologyMICRO (<$300M)

Signal Magnitude Chart

BEARISH | 90% | 3/27/2026 | margin compressionBULLISH | 70% | 3/27/2026 | regulatory actionNEUTRAL | 50% | 3/27/2026 | debt restructureBULLISH | 40% | 3/27/2026 | management changeBEARISH | 70% | 5/15/2026 | margin compressionNEUTRAL | 60% | 5/15/2026 | debt restructureBULLISH | 40% | 5/15/2026 | capital raiseBEARISH | 70% | 5/15/2026 | margin compressionNEUTRAL | 60% | 5/15/2026 | debt restructureBULLISH | 40% | 5/15/2026 | capital raiseMar 26May 26HIGHLOW
bullish
bearish
neutral

Signal Timeline

bearishMay 15

Negative gross margins and inventory write-downs indicate poor unit economics.

margin compression
70%
neutralMay 15

Ninth Amendment to Credit Agreement provides temporary relief but imposes strict repayment terms on new capital.

debt restructure
60%
bullishMay 15

Recent registered direct offering provided a modest cash injection to extend runway.

capital raise
40%
bearishMay 15

Negative gross margins and inventory write-downs indicate poor unit economics.

margin compression
70%
neutralMay 15

Ninth Amendment to Credit Agreement provides temporary relief but imposes strict repayment terms on new capital.

debt restructure
60%
bullishMay 15

Recent registered direct offering provided a modest cash injection to extend runway.

capital raise
40%
bearishMar 27

Revenue declined 73% YoY while net losses remained substantial at $69.9M.

margin compression
90%
bullishMar 27

Submission of sNDA for at-home use of IGALMI to expand total addressable market.

regulatory action
70%
neutralMar 27

Ninth Amendment to Credit Agreement waived going concern qualification but imposed strict liquidity covenants.

debt restructure
50%
bullishMar 27

Appointment of Interim CCO to prepare for potential at-home launch.

management change
40%

Filing History

10-QMay 15, 2026

The 10-Q reveals a company at a crossroads, balancing a high-potential regulatory milestone against a deteriorating balance sheet. While the acceptance of the sNDA and the established PDUFA date provide a clear timeline for value realization, the 'going concern' qualification underscores the urgency of the situation. BioXcel is effectively racing against its own cash burn to reach November 2026. Investors are now weighing the asymmetric upside of a blockbuster at-home label expansion and a subsequent strategic sale against the very real possibility of a liquidity event or bankruptcy. The critical path for the company is no longer just clinical success, but the ability to maintain compliance with its restrictive credit covenants while managing a lean operational footprint.

10-KMar 27, 2026

The 10-K reveals a company at a critical binary juncture. BioXcel has successfully stripped away operational waste to survive until Q2 2026, but it has effectively bet its entire existence on the FDA's acceptance of the SERENITY At-Home data. The shift to an Integrated Delivery Network (IDN) model reflects a pragmatic admission that the company cannot afford a traditional commercial launch, opting instead for a lean structure that favors a strategic buyout or licensing deal. Investors are now weighing a high-risk, high-reward scenario: a regulatory win that unlocks a massive home-care market versus a regulatory failure that leads to a liquidity crisis and potential insolvency. The presence of a fully insured class-action settlement removes one immediate legal overhang, but the fundamental struggle remains the gap between the company's debt obligations and its current revenue generation capabilities.